10-QPeriod: Q1 FY2024

BOSTON SCIENTIFIC CORP Quarterly Report for Q1 Ended Mar 31, 2024

Filed May 1, 2024For Securities:BSX

Summary

Boston Scientific Corporation reported strong financial results for the first quarter of 2024, demonstrating robust top-line growth and improved profitability. Net sales increased by 13.8% to $3.856 billion compared to the prior year, driven by broad-based growth across its MedSurg and Cardiovascular segments, with notable strength in Cardiology and Peripheral Interventions. The company also showed significant improvement in net income, which more than doubled year-over-year, highlighting effective operational execution and expanding margins. The company continues to execute on its strategic priorities, including pending acquisitions. The agreement to acquire Axonics, Inc. is progressing through regulatory review, with expected closure in the second half of 2024. Management expressed confidence in its liquidity and ability to fund operations, investments, and potential acquisitions, supported by a strong cash position and an undrawn revolving credit facility. Overall, the quarter's results indicate positive momentum and a solid foundation for future growth.

Financial Highlights

50 data points
Beta

Revenue

$3.86B

68.7% Gross Margin

Net Income

$495.00M

12.8% Net Margin

EPS (Diluted)

$0.33

Total Assets

$36.67B

Cash & Equivalents

$2.33B

Free Cash Flow

-$15.00M

Financial Statements
Beta
Revenue$3.86B
Cost of Revenue$1.21B
Gross Profit$2.65B
SG&A Expenses$1.36B
Operating Expenses$1.97B
Operating Income$675.00M
Interest Expense$69.00M
Net Income$495.00M
EPS (Basic)$0.34
EPS (Diluted)$0.33
Shares Outstanding (Basic)1.47B
Shares Outstanding (Diluted)1.48B

Key Highlights

  • 1Net sales grew 13.8% year-over-year to $3.856 billion, exceeding the prior year's $3.389 billion.
  • 2Net income attributable to common stockholders significantly increased to $495 million ($0.33 per diluted share) from $300 million ($0.21 per diluted share) in the prior year.
  • 3Gross profit margin remained strong at 68.7%, slightly down from 69.3% in Q1 2023, but the company saw increased sales of higher-margin products.
  • 4The pending acquisition of Axonics, Inc. is proceeding, with a projected closing in the second half of 2024, subject to regulatory approvals.
  • 5Operating expenses increased in line with sales growth, with SG&A up 12% and R&D up 9%, reflecting investments in sales support and product pipeline.
  • 6The company maintained a strong liquidity position with $2.329 billion in unrestricted cash and cash equivalents and no amounts outstanding under its $2.750 billion revolving credit facility.
  • 7The effective tax rate decreased to 18.9% from 29.4% in the prior year, primarily due to acquisition expenses and discrete tax benefits.

Frequently Asked Questions

Revenue growth was primarily driven by strong performance across both the MedSurg and Cardiovascular segments. Key contributors included the Cardiology business, particularly the WATCHMAN FLX™ LAAC Device and electrophysiology products, and the Peripheral Interventions business, boosted by its interventional oncology and drug-eluting portfolios. Broader market expansion and strategic acquisitions also played a role.

Boston Scientific announced its definitive agreement to acquire Axonics, Inc. in January 2024. Both companies have received a 'Second Request' from the FTC, which extends the regulatory review period. The company expects the transaction to be completed in the second half of 2024, contingent upon the satisfaction of customary closing conditions and regulatory approval.

Boston Scientific maintains a strong liquidity position, reporting $2.329 billion in unrestricted cash and cash equivalents as of March 31, 2024. Additionally, the company has a $2.750 billion revolving credit facility, of which no amounts were outstanding. Management believes these resources, combined with expected cash flow from operations, are sufficient to fund operations, investments, and debt obligations for the foreseeable future.

The effective tax rate decreased to 18.9% in Q1 2024 from 29.4% in Q1 2023. This reduction was primarily due to certain charges related to acquisition expenses and discrete tax benefits, including those related to unrecognized tax benefits and stock-based compensation. The prior year's rate was impacted by discrete charges for provision-to-return adjustments.